Literature DB >> 10230814

Defining regions of the Y-chromosome responsible for male infertility and identification of a fourth AZF region (AZFd) by Y-chromosome microdeletion detection.

M Kent-First1, A Muallem, J Shultz, J Pryor, K Roberts, W Nolten, L Meisner, A Chandley, G Gouchy, L Jorgensen, T Havighurst, J Grosch.   

Abstract

Cytogenetic and molecular deletion analyses of azoospermic and oligozoospermic males have suggested the existence of AZoospermia Factor(s) (AZF) residing in deletion intervals 5 and 6 of the human Y-chromosome and coinciding with three functional regions associated with spermatogenic failure. Nonpolymorphic microdeletions in AZF are associated with a broad spectrum of testicular phenotypes. Unfortunately, Sequence Tagged Sites (STSs) employed in screening protocols range broadly in number and mapsite and may be polymorphic. To thoroughly analyze the AZF region(s) and any correlations that may be drawn between genotype and phenotype, we describe the design of nine multiplex PCR reactions derived from analysis of 136 loci. Each multiplex contains 4-8 STS primer pairs, amplifying a total of 48 Y-linked STSs. Each multiplex consists of one positive control: either SMCX or MIC2. We screened four populations of males with these STSs. Population I consisted of 278 patients diagnosed as having significant male factor infertility: either azoospermia, severe oligozoospermia associated with hypogonadism and spermatogenic arrest or normal sperm counts associated with abnormal sperm morphology. Population II consisted of 200 unselected infertile patients. Population III consisted of 36 patients who had previously been shown to have aneuploidy, cytological deletions or translocations involving the Y-chromosome or normal karyotypes associated with severe phenotype abnormalities. Population IV consisted of 920 fertile (control) males. The deletion rates in populations I, II and III were 20.5%, 7% and 58.3%, respectively. A total of 92 patients with deletions were detected. The deletion rate in population IV was 0.87% involving 8 fertile individuals and 4 STSs which were avoided in multiplex panel construction. The ability of the nine multiplexes to detect pathology associated microdeletions is equal to or greater than screening protocols used in other studies. Furthermore, the data suggest a fourth AZF region between AZFb and AZFc, which we have termed AZFd. Patients with microdeletions restricted to AZFd may present with mild oligozoospermia or even normal sperm counts associated with abnormal sperm morphology. Though a definitive genotype/phenotype correlation does not exist, large deletions spanning multiple AZF regions or microdeletions restricted to AZFa usually result in patients with Sertoli Cell Only (SCO) or severe oligozoospermia, whereas microdeletions restricted to AZFb or AZFc can result in patients with phenotypes which range from SCO to moderate oligozoospermia. The panel of nine multiplexed reactions, the Y-deletion Detection System (YDDS), provides a fast, efficient and accurate method of assessing the integrity of the Y-chromosome. To date, this study provides the most extensive screening of a proven fertile male population in tandem with 514 infertile males, derived from three different patient selection protocols.

Entities:  

Mesh:

Year:  1999        PMID: 10230814     DOI: 10.1002/(SICI)1098-2795(199905)53:1<27::AID-MRD4>3.0.CO;2-W

Source DB:  PubMed          Journal:  Mol Reprod Dev        ISSN: 1040-452X            Impact factor:   2.609


  42 in total

Review 1.  The role of human and mouse Y chromosome genes in male infertility.

Authors:  N A Affara; M J Mitchell
Journal:  J Endocrinol Invest       Date:  2000-11       Impact factor: 4.256

Review 2.  Role of the AZFa candidate genes in male infertility.

Authors:  C Foresta; E Moro; A Rossi; M Rossato; A Garolla; A Ferlin
Journal:  J Endocrinol Invest       Date:  2000-11       Impact factor: 4.256

3.  Multiplex PCR for screening of microdeletions on the Y chromosome.

Authors:  P Bor; J Hindkjaer; H J Ingerslev; S Kølvraa
Journal:  J Assist Reprod Genet       Date:  2001-05       Impact factor: 3.412

Review 4.  Do you know the sex of your cells?

Authors:  Kalpit Shah; Charles E McCormack; Neil A Bradbury
Journal:  Am J Physiol Cell Physiol       Date:  2013-11-06       Impact factor: 4.249

5.  Study of microdeletions in the Y chromosome of infertile men with idiopathic oligo- or azoospermia.

Authors:  G Yao; G Chen; T Pan
Journal:  J Assist Reprod Genet       Date:  2001-11       Impact factor: 3.412

6.  The critical region of overlap defining the AZFa male infertility interval of proximal Yq contains three transcribed sequences.

Authors:  C A Sargent; C A Boucher; S Kirsch; G Brown; B Weiss; A Trundley; P Burgoyne; N Saut; C Durand; N Levy; P Terriou; T Hargreave; H Cooke; M Mitchell; G A Rappold; N A Affara
Journal:  J Med Genet       Date:  1999-09       Impact factor: 6.318

7.  Idiopathic cases of male infertility from a region in India show low incidence of Y-chromosome microdeletion.

Authors:  R Ambasudhan; K Singh; J K Agarwal; S K Singh; A Khanna; R K Sah; I Singh; R Raman
Journal:  J Biosci       Date:  2003-09       Impact factor: 1.826

8.  A biopsy sample reduction approach to identify significant alterations of the testicular transcriptome in the presence of Y-chromosomal microdeletions that are independent of germ cell composition.

Authors:  Heike Cappallo-Obermann; Kathrein von Kopylow; Wolfgang Schulze; Andrej-Nikolai Spiess
Journal:  Hum Genet       Date:  2010-07-29       Impact factor: 4.132

9.  Identification of Y chromosome microdeletions in infertile Turkish men.

Authors:  Ali Şahin Küçükaslan; Vildan Bozok Çetintaş; Raşit Altıntaş; Aslı Tetik Vardarlı; Zeynep Mutlu; Murat Ulukuş; Bülent Semerci; Zuhal Eroğlu
Journal:  Turk J Urol       Date:  2013-09

10.  Clinical and genetic aspects of testicular germ cell tumours.

Authors:  Martijn F Lutke Holzik; Rolf H Sijmons; Josette Ehm Hoekstra-Weebers; Dirk T Sleijfer; Harald J Hoekstra
Journal:  Hered Cancer Clin Pract       Date:  2008-02-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.